GH and IGF-1 deficiency are associated with Alzheimer's disease, with evidence that restoring this axis improves cognitive function — positioning GH secretagogues as potential therapeutic agents for neurodegeneration.
Key findingGH/IGF-1 axis decline correlates with Alzheimer's disease progression, with IGF-1 supporting neuronal survival, beta-amyloid clearance, and synaptic f
What the researchers found
GH/IGF-1 axis decline correlates with Alzheimer's disease progression, with IGF-1 supporting neuronal survival, beta-amyloid clearance, and synaptic function — GH secretagogues that restore this axis may offer neuroprotective therapeutic benefit for dementia.
Why it matters
Relevant for hormone-optimization, neuroprotection, anti-aging.
How the study worked
review study.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2008.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Growth hormone and insulin-like growth factor-I as an endocrine axis in Alzheimer's disease.
Endocrine, metabolic & immune disorders drug targets, 8(2), 143-51
Citation
Gómez, José Manuel. (2008). Growth hormone and insulin-like growth factor-I as an endocrine axis in Alzheimer's disease.. Endocrine, metabolic & immune disorders drug targets, 8(2), 143-51.